Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (DBCOND0111186)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05836584	Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer	Atezolizumab Calcium Capecitabine Docetaxel Fluorouracil Leucovorin Levoleucovorin Oxaliplatin	treatment	2	recruiting
NCT06203600	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	Lexatumumab Nivolumab Paclitaxel Ramucirumab	treatment	2 / 3	recruiting
NCT06364410	Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	Azenosertib Trastuzumab deruxtecan	treatment	1	recruiting
NCT03604991	Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery	Carboplatin Ipilimumab Nivolumab Paclitaxel	treatment	2 / 3	suspended
NCT03784326	Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma	Atezolizumab Fluorouracil Oxaliplatin Tiragolumab	treatment	2	recruiting
NCT04391049	Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery	Carboplatin Paclitaxel Suratadenoturev	treatment	1	active_not_recruiting
NCT04535401	Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	Calcium Camptothecin Elimusertib Fluorouracil Irinotecan Leucovorin Levoleucovorin	treatment	1	active_not_recruiting
NCT04704661	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Ceralasertib Trastuzumab deruxtecan	treatment	1	recruiting
NCT05041153	Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	Lenvatinib Pembrolizumab	treatment	0	recruiting
NCT06078709	Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma	Calcium Docetaxel Fluorouracil Leucovorin Levoleucovorin Oxaliplatin	treatment	2	recruiting
NCT05296005	Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers	Capecitabine Docetaxel Fluorouracil Leucovorin Oxaliplatin	treatment	1	not_yet_recruiting
NCT04522336	Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer	Docetaxel Fluorouracil Oxaliplatin Pembrolizumab	treatment	1	active_not_recruiting
NCT03641313	Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	Berzosertib Irinotecan	treatment	2	active_not_recruiting
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Pembrolizumab Sonidegib	treatment	1	recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT05677490	mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma	Fluorouracil Irinotecan Leucovorin Nivolumab Oxaliplatin	treatment	3	recruiting
NCT03776487	Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer	Fluorouracil Ipilimumab Nivolumab Oxaliplatin	treatment	2	active_not_recruiting
NCT04097028	Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma	Oxaliplatin Thymidine Tipiracil Trifluridine	treatment	2	active_not_recruiting
NCT04460937	Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers	Adavosertib	treatment	1	active_not_recruiting
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting
NCT03707574	Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT03801876	Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer	Amoxapine Carboplatin Docetaxel Fluorouracil Paclitaxel	treatment	3	recruiting
NCT04660760	Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	Lexatumumab Paclitaxel Ramucirumab TAS-102 Tipiracil Trifluridine	treatment	2	recruiting
NCT05651594	Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	Fluorouracil Leucovorin Oxaliplatin Pembrolizumab Propranolol	treatment	2	recruiting
NCT04929392	Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer	Carboplatin Lenvatinib Paclitaxel Pembrolizumab	treatment	2	active_not_recruiting